Population antibody responses following COVID-19 vaccination in 212,102 individuals

Helen Ward (), Matthew Whitaker, Barnaby Flower, Sonja N. Tang, Christina Atchison, Ara Darzi, Christl A. Donnelly, Alexandra Cann, Peter J. Diggle, Deborah Ashby, Steven Riley, Wendy S. Barclay, Paul Elliott and Graham S. Cooke ()
Additional contact information
Helen Ward: Imperial College London
Matthew Whitaker: Imperial College London
Barnaby Flower: Imperial College Healthcare NHS Trust
Sonja N. Tang: Imperial College London
Christina Atchison: Imperial College London
Ara Darzi: Imperial College Healthcare NHS Trust
Christl A. Donnelly: Imperial College London
Alexandra Cann: Imperial College Healthcare NHS Trust
Peter J. Diggle: Lancaster University
Deborah Ashby: Imperial College London
Steven Riley: Imperial College London
Wendy S. Barclay: Imperial College London
Paul Elliott: Imperial College London
Graham S. Cooke: Imperial College Healthcare NHS Trust

Nature Communications, 2022, vol. 13, issue 1, 1-6

Abstract: Abstract Population antibody surveillance helps track immune responses to COVID-19 vaccinations at scale, and identify host factors that may affect antibody production. We analyse data from 212,102 vaccinated individuals within the REACT-2 programme in England, which uses self-administered lateral flow antibody tests in sequential cross-sectional community samples; 71,923 (33.9%) received at least one dose of BNT162b2 vaccine and 139,067 (65.6%) received ChAdOx1. For both vaccines, antibody positivity peaks 4-5 weeks after first dose and then declines. At least 21 days after second dose of BNT162b2, close to 100% of respondents test positive, while for ChAdOx1, this is significantly reduced, particularly in the oldest age groups (72.7% [70.9–74.4] at ages 75 years and above). For both vaccines, antibody positivity decreases with age, and is higher in females and those with previous infection. Antibody positivity is lower in transplant recipients, obese individuals, smokers and those with specific comorbidities. These groups will benefit from additional vaccine doses.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-28527-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-28527-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-28527-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().